Advanced search
Publication Cover
Acta Oncologica Volume 48, 2009 - Issue 4
Journal homepage
1,936
Views
40
CrossRef citations to date
0
Altmetric
Letters to the Editor

Flare-up: An often unreported phenomenon nevertheless familiar to oncologists prescribing tyrosine kinase inhibitors

Pascal Wolter Department of General Medical Oncology, University Hospitals Leuven, Catholic University of Leuven, Leuven, BelgiumCorrespondence[email protected]
,
Benoit Beuselinck Department of General Medical Oncology, University Hospitals Leuven, Catholic University of Leuven, Leuven, Belgium
,
Steven Pans Department of Radiology, University Hospitals Leuven, Catholic University of Leuven, Leuven, Belgium
&
Patrick Schöffski Department of General Medical Oncology, University Hospitals Leuven, Catholic University of Leuven, Leuven, Belgium
Pages 621-624 | Received 22 Sep 2008, Published online: 08 Jul 2009

Citations (40)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Maxine Sun, Alessandro Larcher & Pierre I Karakiewicz. (2014) Optimal first-line and second-line treatments for metastatic renal cell carcinoma: current evidence. International Journal of Nephrology and Renovascular Disease 7, pages 401-407.
Read now
Jessie M Wu & Carolyn A Staton. (2012) Anti-angiogenic drug discovery: lessons from the past and thoughts for the future. Expert Opinion on Drug Discovery 7:8, pages 723-743.
Read now
Wanfeng Guo, Xiaoqing Liu & Hongjun Gao. (2011) Flare up of symptoms after discontinuation of sunitinib in patient with lung cancer. Acta Oncologica 50:7, pages 1133-1135.
Read now
Pascal Wolter & Patrick Schöffski. (2010) Targeted therapies in the treatment of GIST: Adverse events and maximising the benefits of sunitinib through proactive therapy management. Acta Oncologica 49:1, pages 13-23.
Read now
Ingrid M. E. Desar, Sasja F. Mulder, Alexander B. Stillebroer, Dick-Johan van Spronsen, Winette T. A. van der Graaf, Peter F. A. Mulders & Carla M. L. van Herpen. (2009) The reverse side of the victory: Flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases. Acta Oncologica 48:6, pages 927-931.
Read now

Articles from other publishers (35)

Xinpu Han, Qianhui Sun, Manman Xu, Guanghui Zhu, Ruike Gao, Baoyi Ni & Jie Li. (2023) Unraveling the Complexities of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma. Seminars in Liver Disease.
Crossref
Paulina Marona, Judyta Górka, Oliwia Kwapisz, Jolanta Jura, Janusz Rys, Robert M. Hoffman & Katarzyna Miekus. (2022) Resistance to tyrosine kinase inhibitors promotes renal cancer progression through MCPIP1 tumor-suppressor downregulation and c-Met activation. Cell Death & Disease 13:9.
Crossref
Donald J. AbrahamLei Shi. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery 1 66 .
Mali Amirault, Sylvia Choo, Timothy Waxweiler, Sarah D. Weisdack, Kathryn Breaker, Thomas W. Flaig & Elaine T. Lam. (2021) Tumor flare of brain metastases upon dose interruption of sunitinib in a patient with metastatic renal cell carcinoma. Cancer Treatment and Research Communications 27, pages 100367.
Crossref
Laiyan Zhou, Mai Zhang, Rui Li, Jianxin Xue & You Lu. (2020) Pseudoprogression and hyperprogression in lung cancer: a comprehensive review of literature. Journal of Cancer Research and Clinical Oncology 146:12, pages 3269-3279.
Crossref
Min-Hee Kim, Tae Hyeong Lee, Jin Soo Lee, Dong-Jun Lim & Peter Chang-Whan Lee. (2020) Hif-1α Inhibitors Could Successfully Inhibit the Progression of Differentiated Thyroid Cancer in Vitro. Pharmaceuticals 13:9, pages 208.
Crossref
Rossella Rodia, Stefano Marini, Fabiana Pani, Francesco Boi & Stefano Mariotti. (2019) Embolization of iliac metastasis during lenvatinib treatment in patient with advanced Hürthle cell thyroid carcinoma. Future Oncology 15:24s, pages 35-40.
Crossref
Stéphane Champiat, Roberto Ferrara, Christophe Massard, Benjamin Besse, Aurélien Marabelle, Jean-Charles Soria & Charles Ferté. (2018) Hyperprogressive disease: recognizing a novel pattern to improve patient management. Nature Reviews Clinical Oncology 15:12, pages 748-762.
Crossref
Nili Dahan, Ksenia Magidey & Yuval Shaked. 2018. Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways. Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways 211 236 .
Satoshi Okamori, Takanori Asakura, Keita Masuzawa, Hiroyuki Yasuda, Hirofumi Kamata, Makoto Ishii & Tomoko Betsuyaku. (2017) Suspected accelerated disease progression after discontinuation of nintedanib in patients with idiopathic pulmonary fibrosis. Medicine 96:49, pages e9081.
Crossref
Sebastiano Buti, Maddalena Donini, Melissa Bersanelli, Alessia Gattara, Francesco Leonardi & Rodolfo Passalacqua. (2017) Feasibility, Safety, and Efficacy of an Alternative Schedule of Sunitinib for the Treatment of Patients with Metastatic Renal Cell Carcinoma: A Retrospective Study. Drugs in R&D 17:4, pages 585-596.
Crossref
Fabiana Pani, Elisabetta Macerola, Fulvio Basolo, Francesco Boi, Mario Scartozzi & Stefano Mariotti. (2017) Aggressive differentiated thyroid cancer with multiple metastases and NRAS and TERT promoter mutations: A case report. Oncology Letters 14:2, pages 2186-2190.
Crossref
Sebastiano Buti & Melissa Bersanelli. (2017) Is Cabozantinib Really Better Than Sunitinib As First-Line Treatment of Metastatic Renal Cell Carcinoma?. Journal of Clinical Oncology 35:16, pages 1858-1859.
Crossref
Brian M. Shinder, Kevin Rhee, Douglas Farrell, Nicholas J. Farber, Mark N. Stein, Thomas L. Jang & Eric A. Singer. (2017) Surgical Management of Advanced and Metastatic Renal Cell Carcinoma: A Multidisciplinary Approach. Frontiers in Oncology 7.
Crossref
Terumi Tanigawa, Shintaro Morisaki, Hisanobu Fukuda, Shuichiro Yoshimura, Hisayoshi Nakajima & Kohei Kotera. (2017) Tumors Sharply Increased after Ceasing Pazopanib Therapy for a Patient with Advanced Uterine Leiomyosarcoma: Experience of Tumor Flare. Case Reports in Obstetrics and Gynecology 2017, pages 1-4.
Crossref
Amr Shaaban Hanafy. (2016) Efficacy of low dose capecitabine and sorafenib in patients with advanced alfa-fetoprotein secreting hepatocellular carcinoma: a 1 year experience. SpringerPlus 5:1.
Crossref
Ewa Maj, Diana Papiernik & Joanna Wietrzyk. (2016) Antiangiogenic cancer treatment: The great discovery and greater complexity (Review). International Journal of Oncology 49:5, pages 1773-1784.
Crossref
Julien Langrand-Escure, Alexis Vallard, Romain Rivoirard, Benoîte Méry, Jean-Baptiste Guy, Sophie Espenel, Jane-Chloé Trone, Majed Ben Mrad, Peng Diao, Chloé Rancoule, Jean-Philippe Suchaud, Pierre Fournel, Aline Guillot, Cyrus Chargari, Bernard Escudier, Sylvie Négrier & Nicolas Magné. (2016) Safety assessment of molecular targeted therapies in association with radiotherapy in metastatic renal cell carcinoma. Anti-Cancer Drugs 27:5, pages 427-432.
Crossref
Dong-Hoe Koo, Inkeun Park, Jin-Hee Ahn, Dae-Ho Lee, Dalsan You, In-Gab Jeong, Cheryn Song, Bumsik Hong, Jun Hyuk Hong, Hanjong Ahn & Jae-Lyun Lee. (2015) Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma. Cancer Chemotherapy and Pharmacology 77:2, pages 339-347.
Crossref
Ciska-Anne Van Keerberghen, Johnny Jean-Baptiste, Pascal Wolter, Jessica Zucman-Rossi, Patrick Schöffski & Benoit Beuselinck. (2015) Direct Visualization of the Antiangiogenic Effects of Sunitinib During the Treatment of Metastatic Clear Cell Renal Cell Carcinoma. Clinical Genitourinary Cancer 13:6, pages e407-e410.
Crossref
Vittorio Fusco, Camillo Porta, Giorgia Saia, Chiara Paglino, Giordana Bettini, Matteo Scoletta, Riccardo Bonacina, Paolo Vescovi, Elisabetta Merigo, Giovanni Lo Re, Pamela Guglielmini, Olga Di Fede, Giuseppina Campisi & Alberto Bedogni. (2015) Osteonecrosis of the Jaw in Patients With Metastatic Renal Cell Cancer Treated With Bisphosphonates and Targeted Agents: Results of an Italian Multicenter Study and Review of the Literature. Clinical Genitourinary Cancer 13:4, pages 287-294.
Crossref
Fancesco Maria Guida, Matteo Santoni, Alessandro Conti, Luciano Burattini, Agnese Savini, Tea Zeppola, Marco Caricato, Stefano Cascinu, Giuseppe Tonini & Daniele Santini. (2014) Alternative dosing schedules for sunitinib as a treatment of patients with metastatic renal cell carcinoma. Critical Reviews in Oncology/Hematology 92:3, pages 208-217.
Crossref
Naveen S. Vasudev & Andrew R. Reynolds. (2014) Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis 17:3, pages 471-494.
Crossref
Maxine Sun, Quoc-Dien Trinh, Paul Perrotte & Pierre I. Karakiewicz. (2014) Re: Pazopanib Versus Sunitinib in Metastatic Renal-cell Carcinoma. European Urology 65:5, pages 1014-1015.
Crossref
Kyung-Jin YunWoohyeon KimEun Hee KimMin-Hee KimDong-Jun LimMoo-Il KangBong-Yun Cha. (2014) Accelerated Disease Progression after Discontinuation of Sorafenib in a Patient with Metastatic Papillary Thyroid Cancer. Endocrinology and Metabolism 29:3, pages 388.
Crossref
S. Bellou, G. Pentheroudakis, C. Murphy & T. Fotsis. (2013) Anti-angiogenesis in cancer therapy: Hercules and hydra. Cancer Letters 338:2, pages 219-228.
Crossref
Grace K. Dy & Alex A. Adjei. (2013) Understanding, recognizing, and managing toxicities of targeted anticancer therapies. CA: A Cancer Journal for Clinicians 63:4, pages 249-279.
Crossref
John M.L. Ebos & Roberto Pili. (2012) Mind the Gap: Potential for Rebounds during Antiangiogenic Treatment Breaks. Clinical Cancer Research 18:14, pages 3719-3721.
Crossref
Arjan W. Griffioen, Laurie A. Mans, Annemarie M.A. de Graaf, Patrycja Nowak-Sliwinska, Céline L.M.M. de Hoog, Trees A.M. de Jong, Florry A. Vyth-Dreese, Judy R. van Beijnum, Axel Bex & Eric Jonasch. (2012) Rapid Angiogenesis Onset after Discontinuation of Sunitinib Treatment of Renal Cell Carcinoma Patients. Clinical Cancer Research 18:14, pages 3961-3971.
Crossref
Florence Joly. (2011) Cancer du rein et fatigue : quels enjeux à l’ère des antiangiogéniques ?. Bulletin du Cancer 98:9, pages 1071-1081.
Crossref
T. Powles, S. Chowdhury, J. Shamash, A. Bazeos, S. Gillessen, N. Saunders, L. Lim, N. Sarwar, A. Sadev, P. Wilson, P. Nathan, K. Boleti, J. Peters & S. Agrawal. (2011) Increased haematopoietic progenitor cells are associated with poor outcome in patients with metastatic renal cancer treated with sunitinib. Annals of Oncology 22:4, pages 815-820.
Crossref
John M. L. Ebos & Robert S. Kerbel. (2011) Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nature Reviews Clinical Oncology 8:4, pages 210-221.
Crossref
James M.G. LarkinLynda M. PyleMartin E. Gore. (2010) Fatigue in Renal Cell Carcinoma: The Hidden Burden of Current Targeted Therapies. The Oncologist 15:11, pages 1135-1146.
Crossref
Terence C. Tang, Shan Man, Ping Xu, Giulio Francia, Kae Hashimoto, Urban Emmenegger & Robert S. Kerbel. (2010) Development of a Resistance-like Phenotype to Sorafenib by Human Hepatocellular Carcinoma Cells Is Reversible and Can Be Delayed by Metronomic UFT Chemotherapy. Neoplasia 12:11, pages 928-940.
Crossref
John M. L. Ebos, Christina R. Lee & Robert S. Kerbel. (2009) Tumor and Host-Mediated Pathways of Resistance and Disease Progression in Response to Antiangiogenic Therapy. Clinical Cancer Research 15:16, pages 5020-5025.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.